These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 31276989)

  • 21. Early Tolerance and Tumor Control Outcomes with High-dose Ultrahypofractionated Radiation Therapy for Prostate Cancer.
    Zelefsky MJ; Pinitpatcharalert A; Kollmeier M; Goldman DA; McBride S; Gorovets D; Zhang Z; Varghese M; Happersett L; Tyagi N; Hunt M
    Eur Urol Oncol; 2020 Dec; 3(6):748-755. PubMed ID: 31668713
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stereotactic body radiation therapy for low and intermediate risk prostate cancer-Results from a multi-institutional clinical trial.
    Hannan R; Tumati V; Xie XJ; Cho LC; Kavanagh BD; Brindle J; Raben D; Nanda A; Cooley S; Kim DWN; Pistenmaa D; Lotan Y; Timmerman R
    Eur J Cancer; 2016 May; 59():142-151. PubMed ID: 27035363
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: early results.
    Aluwini S; van Rooij P; Hoogeman M; Kirkels W; Kolkman-Deurloo IK; Bangma C
    Radiat Oncol; 2013 Apr; 8():84. PubMed ID: 23570391
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography.
    Kneebone A; Hruby G; Ainsworth H; Byrne K; Brown C; Guo L; Guminski A; Eade T
    Eur Urol Oncol; 2018 Dec; 1(6):531-537. PubMed ID: 31158100
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prostate Stereotactic Body Radiation Therapy With a Focal Simultaneous Integrated Boost: 5-Year Toxicity and Biochemical Recurrence Results From a Prospective Trial.
    Maas JA; Dobelbower MC; Yang ES; Clark GM; Jacob R; Kim RY; Cardan RA; Popple R; Nix JW; Rais-Bahrami S; Fiveash JB; McDonald AM
    Pract Radiat Oncol; 2023; 13(5):466-474. PubMed ID: 37268193
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Linac-based stereotactic salvage reirradiation for intraprostatic prostate cancer recurrence: toxicity and outcomes.
    Cozzi S; Finocchi Ghersi S; Bardoscia L; Najafi M; Blandino G; Alì E; Augugliaro M; Vigo F; Ruggieri MP; Cardano R; Giaccherini L; Iori F; Botti A; Trojani V; Ciammella P; Iotti C
    Strahlenther Onkol; 2023 Jun; 199(6):554-564. PubMed ID: 36732443
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Simultaneous Focal Boost With Stereotactic Radiation Therapy for Localized Intermediate- to High-Risk Prostate Cancer: Primary Outcomes of the SPARC Phase 2 Trial.
    Yasar B; Suh YE; Chapman E; Nicholls L; Henderson D; Jones C; Morrison K; Wells E; Henderson J; Meehan C; Sohaib A; Taylor H; Tree A; van As N
    Int J Radiat Oncol Biol Phys; 2024 Sep; 120(1):49-58. PubMed ID: 38499253
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety of accelerated hypofractionated whole pelvis radiation therapy prior to high dose rate brachytherapy or stereotactic body radiation therapy prostate boost.
    Phuong C; Chan JW; Ni L; Wall P; Mohamad O; Wong AC; Hsu IC; Chang AJ
    Radiat Oncol; 2022 Jan; 17(1):12. PubMed ID: 35057827
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acute side effects after definitive stereotactic body radiation therapy (SBRT) for patients with clinically localized or locally advanced prostate cancer: a single institution prospective study.
    Jorgo K; Polgar C; Stelczer G; Major T; Gesztesi L; Agoston P
    Radiol Oncol; 2021 Jul; 55(4):474-481. PubMed ID: 34253001
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies.
    Jackson WC; Silva J; Hartman HE; Dess RT; Kishan AU; Beeler WH; Gharzai LA; Jaworski EM; Mehra R; Hearn JWD; Morgan TM; Salami SS; Cooperberg MR; Mahal BA; Soni PD; Kaffenberger S; Nguyen PL; Desai N; Feng FY; Zumsteg ZS; Spratt DE
    Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):778-789. PubMed ID: 30959121
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quality-of-Life Outcomes and Toxicity Profile Among Patients With Localized Prostate Cancer After Radical Prostatectomy Treated With Stereotactic Body Radiation: The SCIMITAR Multicenter Phase 2 Trial.
    Ma TM; Ballas LK; Wilhalme H; Sachdeva A; Chong N; Sharma S; Yang T; Basehart V; Reiter RE; Saigal C; Chamie K; Litwin MS; Rettig MB; Nickols NG; Yoon SM; Smith L; Gao Y; Steinberg ML; Cao M; Kishan AU
    Int J Radiat Oncol Biol Phys; 2023 Jan; 115(1):142-152. PubMed ID: 36007724
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy.
    De Bleser E; Jereczek-Fossa BA; Pasquier D; Zilli T; Van As N; Siva S; Fodor A; Dirix P; Gomez-Iturriaga A; Trippa F; Detti B; Ingrosso G; Triggiani L; Bruni A; Alongi F; Reynders D; De Meerleer G; Surgo A; Loukili K; Miralbell R; Silva P; Chander S; Di Muzio NG; Maranzano E; Francolini G; Lancia A; Tree A; Deantoni CL; Ponti E; Marvaso G; Goetghebeur E; Ost P
    Eur Urol; 2019 Dec; 76(6):732-739. PubMed ID: 31331782
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical outcomes of whole pelvis radiotherapy and stereotactic body radiotherapy boost for intermediate- and high-risk prostate cancer.
    Kim HJ; Phak JH; Kim WC
    Asia Pac J Clin Oncol; 2017 Oct; 13(5):e342-e347. PubMed ID: 26846353
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II study of accelerated Linac-based SBRT in five consecutive fractions for localized prostate cancer.
    Alongi F; Mazzola R; Fiorentino A; Corradini S; Aiello D; Figlia V; Gregucci F; Ballario R; Cavalleri S; Ruggieri R
    Strahlenther Onkol; 2019 Feb; 195(2):113-120. PubMed ID: 30003292
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Moderate versus extreme hypofractionated radiotherapy: a toxicity comparative analysis in low- and favorable intermediate-risk prostate cancer patients.
    Nicosia L; Mazzola R; Rigo M; Figlia V; Giaj-Levra N; Napoli G; Ricchetti F; Corradini S; Ruggieri R; Alongi F
    J Cancer Res Clin Oncol; 2019 Oct; 145(10):2547-2554. PubMed ID: 31324979
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stereotactic body radiotherapy for renal cell cancer and pancreatic cancer : Literature review and practice recommendations of the DEGRO Working Group on Stereotactic Radiotherapy.
    Panje C; Andratschke N; Brunner TB; Niyazi M; Guckenberger M
    Strahlenther Onkol; 2016 Dec; 192(12):875-885. PubMed ID: 27778052
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I/IIa trial of androgen deprivation therapy, external beam radiotherapy, and stereotactic body radiotherapy boost for high-risk prostate cancer (ADEBAR).
    Kim YJ; Ahn H; Kim CS; Kim YS
    Radiat Oncol; 2020 Oct; 15(1):234. PubMed ID: 33032643
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exploring All Avenues for Radiotherapy in Oligorecurrent Prostate Cancer Disease Limited to Lymph Nodes: A Systematic Review of the Role of Stereotactic Body Radiotherapy.
    Ponti E; Lancia A; Ost P; Trippa F; Triggiani L; Detti B; Ingrosso G
    Eur Urol Focus; 2017 Dec; 3(6):538-544. PubMed ID: 28801240
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensus.
    Jereczek-Fossa BA; Marvaso G; Zaffaroni M; Gugliandolo SG; Zerini D; Corso F; Gandini S; Alongi F; Bossi A; Cornford P; De Bari B; Fonteyne V; Hoskin P; Pieters BR; Tree AC; Arcangeli S; Fuller DB; Franzese C; Hannoun-Levi JM; Janoray G; Kerkmeijer L; Kwok Y; Livi L; Loi M; Miralbell R; Pasquier D; Pinkawa M; Scher N; Scorsetti M; Shelan M; Toledano A; van As N; Vavassori A; Zilli T; Pepa M; Ost P;
    Cancer Treat Rev; 2021 Jul; 98():102206. PubMed ID: 33965893
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Salvage re-irradiation using stereotactic body radiation therapy for locally recurrent prostate cancer: the impact of castration sensitivity on treatment outcomes.
    Lewin R; Amit U; Laufer M; Berger R; Dotan Z; Domachevsky L; Davidson T; Portnoy O; Tsvang L; Ben-Ayun M; Weiss I; Symon Z
    Radiat Oncol; 2021 Jun; 16(1):114. PubMed ID: 34162398
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.